Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the initiation of a Phase 1b clinical trial for its self-developed new drug, XH-S004, designed for the treatment of chronic obstructive pulmonary disease (COPD) in China, excluding the Hong Kong SAR, Macau SAR, and Taiwan region. Developed by S-INFINITY Co., Ltd., a subsidiary of Fosun Pharma, XH-S004 is a small molecule oral DPP-1 inhibitor. It targets neutrophils by inhibiting DPP-1 and neutrophil-activated serine proteases, aiming to reduce chronic inflammatory responses and associated airway damage in COPD. The drug seeks to address a significant unmet need in COPD treatment, as current therapies have limited efficacy in preventing acute exacerbations or slowing disease progression. Additionally, XH-S004 is undergoing a Phase II clinical trial for the treatment of non-cystic fibrosis bronchiectasis in Mainland China. No results from the current trial have been presented yet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.